Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research & Development In Brief

This article was originally published in The Tan Sheet

Executive Summary

Benefit of aspirin in diabetics unproven: The benefit of aspirin in diabetic subjects with no cardiovascular disease remains unproven, according to a meta-analysis published in the British Medical Journal. The research, led by Giorgia De Berardis, Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Italy, evaluated six randomized controlled trials. It found no statistically significant reduction in the risk of major cardiovascular events when aspirin was compared with placebo. Future studies should evaluate gender and toxicity, the researchers say. The findings contrast with prevailing beliefs based on trials in populations at higher risk of cardiac events, they add. "We cannot recommend using aspirin in the primary prevention of cardiovascular events in all patients with diabetes without additional evidence.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS103601

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel